Evidence map›Paper›PMID 30614014›Full record

ArticleStatistics in medicine2019

Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression.

Xuelin Huang, Lei Liu, Jing Ning, Liang Li, Yu Shen

Abstract read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1192-9336
Lei LiuDivision of Biostatistics, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1844-338X
Jing NingDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Liang LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5453-3839
Yu ShenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Susan K Peterson · 2002 to 2026
$23.8M
Comparative Modeling: Informing Breast Cancer Control Practice & PolicyU01CA152958 · NCI · GEORGETOWN UNIVERSITY · PI BERRY, DONALD A, DE KONING, HARRY J · 2010 to 2015
$7.6M
Innovative methods for modeling longitudianl medical costsR01HS020263 · AHRQ · UNIVERSITY OF VIRGINIA · PI LIU, LEI · 2011 to 2015
$2.0M
Comparative Effectiveness of Cancer Research: Use Data from Multiple SourcesR01CA193878 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NING, JING · 2016 to 2019
$1.2M
AHRQ HHS R01 HS020263NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA193878NCI NIH HHS U01 CA152958NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

Most studies characterize longitudinal biomarker trajectories by looking forward at them from a commonly used time origin, such as the initial treatment time. For a better understanding of the relationship between biomarkers and disease progression, we propose to align all subjects by using their disease progression time as the origin and then looking backward at the biomarker distributions prior to that event. We demonstrate that such backward-looking plots are much more informative than forward-looking plots when the research goal is to understand the shape of the trajectory leading up to the event of interest. Such backward-looking plotting is an easy task if disease progression is observed for all the subjects. However, when these events are censored for a significant proportion of subjects in the study cohort, their time origins cannot be identified, and the task of aligning them cannot be performed. We propose a new method to tackle this problem by considering the distributions of longitudinal biomarker data conditional on the failure time. We use landmark analysis models to estimate these distributions. Compared to a naïve method, our new method greatly reduces estimation bias. We apply our method to a study for chronic myeloid leukemia patients whose BCR-ABL transcript expression levels after treatment are good indicators of residual disease. Our proposed method provides a good visualization tool for longitudinal biomarker studies for the early detection of disease.

Indexed as

Disease ProgressionBiomarkersHumansLongitudinal StudiesModels, StatisticalSurvival AnalysisBiomarkersbiomarkerdisease recurrencelandmark analysissurvival analysis

Identifiers

PMID30614014
PMCPMC6501595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.